Navigation Links
Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
Date:4/15/2013

SAN DIEGO, April 15, 2013 /PRNewswire/ -- Ambit Biosciences Corporation today announced that David R. Parkinson , M.D., has been appointed to the company's board of directors. Dr. Parkinson is a venture partner at New Enterprise Associates, a position he has held since 2012, and a member of the board of directors for Threshold Pharmaceuticals, a publicly-traded oncology company, and Zyngenia, Inc. He served as a director of Facet Biotech through its acquisition by Abbott in 2010. 

Prior to joining New Enterprise Associates, Dr. Parkinson was president and chief executive officer of Nodality, a biotechnology company focused on personalized medicine. Before this, he held positions as senior vice president of oncology research at Biogen Idec, vice president of oncology development at Amgen, Inc, and vice president of global clinical oncology development at Novartis Corporation. Dr. Parkinson previously held multiple positions with the National Cancer Institute from 1990 to 1997, including chief of the Investigational Drug Branch and associate director of the Cancer Therapy Evaluation Program. He has also served on the National Cancer Policy Forum of the Institute of Medicine and is a past president of the International Society of Biological Therapy. He is a past Chairman of the FDA's Biologics Advisory Committee and member of the FDA Science Board, and is a recipient of the FDA's Cody Medal .  Dr. Parkinson received his medical doctorate from the University of Toronto Faculty of Medicine, with internal medicine and hematology/oncology training at McGill University in Montreal and at New England Medical Center in Boston. He has held academic positions at the M.D. Anderson Cancer Center, University of Texas and New England Medical Center at Tufts University School of Medicine.

"David brings to Ambit extensive medical and industry experience in oncology, which we believe will bring an appropriate perspective for Ambit at this stage," said Michael Martino , President and CEO of Ambit. "We look forward to his contributions toward the development of quizartinib and the rest of our pipeline."

Added Dr. Parkinson, "I look forward to serving as a director and working with the board and management team to help advance the potentially important new therapeutic agents in the Ambit pipeline."

About Ambit Biosciences

Ambit is a privately held biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently under clinical development in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.

Contacts:
Ian Stone or David Schull (Media)
Russo Partners
(619) 308-6541
(212) 845-4271
ian.stone@russopartnersllc.com  
david.schull@russopartnersllc.com


'/>"/>
SOURCE Ambit Biosciences Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
2. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
3. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
4. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
5. Cleave Biosciences Adds New Investor and $10 Million to Series A Financing
6. Neurocrine Biosciences Announces the Start of Phase IIb Study of Elagolix in Uterine Fibroids
7. Industry Veteran Katrine Bosley Joins Genocea Biosciences Board Of Directors
8. Pressure BioSciences, Inc. to Present at the SeeThruEquity Spring Investor Microcap Forum
9. Neurocrine Biosciences To Present At The 25th Annual Roth Conference
10. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
11. Presage Biosciences Announces Strategic Research Alliance with Celgene Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 3, 2016  Specialty Silicone Fabricators ... that shows how a cleanroom works. The free ... about science and technology. ... a technology company, SSF enthusiastically supports the Science, ... educators foster the next generation of innovators. We ...
(Date:5/2/2016)... -- Kalorama Information noted the 5 Most Important Trends ... recent white paper.  The healthcare market research publisher said ... market are among the top drivers of market growth. ... EMR 2016: The Market for Electronic Medical Records ... the EMR industry, and the report is consulted by ...
(Date:5/2/2016)... 2016 The global  ultrasound ... billion by 2024, according to a new report ... of the sonography market include expanding applications of ... for periodic ultrasound screenings of the breast for ... ) High Intensity Focused Ultrasound ...
Breaking Medicine Technology:
(Date:5/4/2016)... Carlsbad, CA (PRWEB) , ... May 04, 2016 , ... ... has recently partnered with local company MitoXcell in preparation of the launch of her ... day jump start plan is a nutritional guide designed to jump start a new ...
(Date:5/4/2016)... ... May 04, 2016 , ... The preeminent surgical aftercare ... Dickinson needed following breast cancer surgery. In March 2016, the 61-year-old model and reality ... breast cancer that occurs in the milk ducts, according to an interview with ...
(Date:5/4/2016)... ... ... Advanced Spine & Sport Medical Rehabilitation Center, which is renowned for its ... seminar on stem cell injections. The seminar is scheduled for Wednesday, May 18, from ... Suite 110, Ventura, CA. There are only 10 seats available. , “The purpose ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... and support for knees, ankles, and elbows. Engineered with athletes in mind, ... flat-bed manufacturing (opposed to ineffective circular knitting, common in the industry) produces ...
(Date:5/4/2016)... , ... May 03, ... manufacturer of innovative infant and child products, today revealed the non-toxic ... ability to help babies deal with teething pain is just part ... no toxic gels, and are BPA-, PVC-, and phthalate-free. , ...
Breaking Medicine News(10 mins):